References

1.

Bell SM. 1975. The cds disc method of antibiotic sensitivity testing (calibrated dichotomous sensitivity test). Pathology 7:1–48.

2.

Ericsson HM, Sherris JC. 1971. Antibiotic sensitivity testing. Report of an international collaborative study. Acta pathologica et microbiologica Scandinavica Section B: Microbiology and immunology 217:1–90.

3.

Humphrey JH, Lightbown JW. 1952. A general theory for plate assay of antibiotics with some practical applications. Journal of General Microbiology 7:129–143.

4.

Outhred A, Bell S, Pham J, Varettas K, Rafferty D. 2006. Annual conference of the australian society for microbiologyPerformance of a disposable plastic inoculating needle in the preparation of the CDS inoculum.

5.

Williamson R, Le Bouquenec C, Gutmann L, Horaud T. 1985. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of enterococcus faecium to benzylpenicillin. Journal of General Microbiology 131:1933–1940.

6.

Bell S, Pham J, Saab J, Nguyen T. 2012. Calibration of doxycycline for use in urinary tract infections with enterococci. Pathology 44:654.

7.

Murray BE. 1990. The life and times of the enterococcus. Clinical Microbiology Reviews 3:46–65.

8.

Disease Control C for, Prevention. 2002. Staphylococcus aureus resistant to vancomycin united states, 2002. Morbidity and Mortality Weekly Report 51:565–67.

9.

Hiramatsu K. 1997. Methicillin-resistant staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 40:135–136.

10.

Afzal-Shah M, Villar HE, Livermore DM. 1999. Biochemical characteristics of a carbapenemase from an acinetobacter baumannii isolate collected in Buenos Aires, Argentina. Journal of Antimicrobial Chemotherapy 43:127–131.

11.

Chu Y-W, Afzal-Shah M, Houang ETS, Palepou M-FI, Lyon DJ, Woodford N, Livermore DM. 2001. IMP-4, a novel metallo-β-lactamase from nosocomial acinetobacter spp. Collected in hong kong between 1994 and 1998. Antimicrobial Agents and Chemotherapy 45:710–714.

12.

Walsh T. 1997. Distribution and expression of beta-lactamase genes among aeromonas spp. Journal of Antimicrobial Chemotherapy 40:171–178.

13.

Kirby JT, Sader HS, Walsh TR, Jones RN. 2004. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: Report from the SENTRY antimicrobial surveillance program (1997-2001). Journal of Clinical Microbiology 42:445–448.

14.

Thomson K. 2001. Controversies about extended-spectrum and AmpC beta-lactamases. Emerging Infectious Diseases 7:333–334.

15.

Yagi T, Wachino J, Kurokawa H, Suzuki S, Yamane K, Doi Y, Shibata N, Kato H, Shibayama K, Arakawa Y. 2005. Practical methods using boronic acid compounds for identification of class c β-lactamase-producing \(\less\)i\(\greater\)klebsiella pneumoniae\(\less\)/i\(\greater\) and \(\less\)i\(\greater\)escherichia coli\(\less\)/i\(\greater\). Journal of Clinical Microbiology 43:2551–2558.

16.

Coudron PE. 2005. Inhibitor-based methods for detection of plasmid-mediated AmpC β-lactamases in \(\less\)i\(\greater\)klebsiella\(\less\)/i\(\greater\) spp., \(\less\)I\(\greater\)escherichia coli\(\less\)/i\(\greater\) , and \(\less\)i\(\greater\)proteus mirabilis\(\less\)/i\(\greater\). Journal of Clinical Microbiology 43:4163–4167.

17.

Pham JN. 2000. The beta-lactamases and beta-lactam antibiotic susceptibility of yersinia enterocolitica. Journal of Antimicrobial Chemotherapy 46:951–957.

18.

Mezzatesta ML, Gona F, Stefani S. 2012. Enterobacter cloacae complex: Clinical impact and emerging antibiotic resistance. Future Microbiology 7:887–902.

19.

Janda JM, Abbott SL, Cheung WK, Hanson DF. 1994. Biochemical identification of citrobacteria in the clinical laboratory. Journal of Clinical Microbiology 32:1850–1854.

20.

Goldstein FW. 2002. Cephalosporinase induction and cephalosporin resistance: A longstanding misinterpretation. Clinical Microbiology and Infection 8:823–825.

21.

Harris PNA, Ferguson JK. 2012. Antibiotic therapy for inducible AmpC β-lactamase-producing gram-negative bacilli: What are the alternatives to carbapenems, quinolones and aminoglycosides? International Journal of Antimicrobial Agents 40:297–305.

22.

Choi S-H, Lee JE, Park SJ, Choi S-H, Lee S-O, Jeong J-Y, Kim M-N, Woo JH, Kim YS. 2008. Emergence of antibiotic resistance during therapy for infections caused by enterobacteriaceae producing AmpC β-lactamase: Implications for antibiotic use. Antimicrobial Agents and Chemotherapy 52:995–1000.

23.

Underwood S. 2004. Citrobacter koseri and citrobacter amalonaticus isolates carry highly divergent  -lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology. Journal of Antimicrobial Chemotherapy 53:1076–1080.

24.

Yan J-J, Ko W-C, Jung Y-C, Chuang C-L, Wu J-J. 2002. Emergence of \(\less\)i\(\greater\)klebsiella pneumoniae\(\less\)/i\(\greater\) isolates producing inducible DHA-1 β-lactamase in a university hospital in taiwan. Journal of Clinical Microbiology 40:3121–3126.

25.

Butt T, Ahmad RN, Mahmood A, Zaidi S. 2003. Ciprofloxacin treatment failure in typhoid fever case, pakistan. Emerging Infectious Diseases 9:1621–1622.

26.

Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P. 1999. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. Journal of Clinical Microbiology 37:3572–3577.

27.

Butler T, Sridhar CB, Daga MK, Pathak K, Pandit RB, Khakhria R, Potkar CN, Zelasky MT, Johnson RB. 1999. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in india. Journal of Antimicrobial Chemotherapy 44:243–250.

28.

Crump JA, Mintz ED. 2010. Global trends in typhoid and paratyphoid fever. Clinical Infectious Diseases 50:241–246.

29.

Gordon MA, Kankwatira AMK, Mwafulirwa G, Walsh AL, Hopkins MJ, Parry CM, Faragher EB, Zijlstra EE, Heyderman RS, Molyneux ME. 2010. Invasive non-typhoid salmonellae establish systemic intracellular infection in HIV-infected adults: An emerging disease pathogenesis. Clinical Infectious Diseases 50:953–962.

30.

Raz R. 2012. Fosfomycin: An oldnew antibiotic. Clinical Microbiology and Infection 18:4–7.

31.

Tristram S, Jacobs MR, Appelbaum PC. 2007. Antimicrobial resistance in haemophilus influenzae. Clinical Microbiology Reviews 20:368–389.

32.

Bell SM, Pham JN, Lanzarone JYM. 1985. Mutation of Pseudomonas aeruginosato piperadillin resistance mediated by β-lactamase production. Journal of Antimicrobial Chemotherapy 15:665–670.

33.

Queenan AM, Bush K. 2007. Carbapenemases: The versatile β-lactamases. Clinical Microbiology Reviews 20:440–458.

34.

White DG, Hudson C, Maurer JJ, Ayers S, Zhao S, Lee MD, Bolton L, Foley T, Sherwood J. 2000. Characterization of chloramphenicol and florfenicol resistance in escherichia coli associated with bovine diarrhea. Journal of Clinical Microbiology 38:4593–4598.

35.

Silley P, Stephan B, Greife HA, Pridmore A. 2012. Bactericidal properties of pradofloxacin against veterinary pathogens. Veterinary Microbiology 157:106–111.

36.

Mahrer S, Reinbott P, Bell SM. 2008. Australian society for microbiology annual conferenceBlood cultures – a retrospective evaluation of direct antibiotic susceptibility testing using positive broth cultures detected by the BacT/alert system.

37.

Mukerjee C, Reiss-Levy E. 1994. Evaluation of direct disc diffusion susceptibility testing for bacteriuria using diluted urine against standard cds method. Pathology 26:201–207.

38.

Fisher G, Simos A, Bell SM. 2005. Australian society for microbiology annual conferenceDirect sensitivity testing of urine samples based on the microscopic quantitation and morphology of organisms.